EU Representative

Akros’s EU Representative’s identity and contact information for subjects of the Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS) officially titled “A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of JTE-451 Administered for 16 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)”:

activeMind.legal
Rechtsanwaltsgesellschaft m.b.H
Kurfürstendamm 56
10707 Berlin, Germany

Tel: +49 (0) 30 / 770 19 10 70
E-mail: PrivacyContact@akrospharma.com
Web: www.activemind.legal